# GentiBio

> GentiBio is a clinical-stage biotechnology company in Cambridge, Massachusetts building engineered regulatory T cell (EngTreg) therapies designed to restore immune tolerance and durably treat autoimmune, autoinflammatory, alloimmune, and allergic diseases. Spun out of research from Seattle Children's, Benaroya Research Institute, and MIGAL Galilee Research Institute, the company combines gene editing of FOXP3 with a modular Treg engineering and manufacturing platform. Its lead program, GNTI-122, is an autologous antigen-specific Treg therapy for recently diagnosed type 1 diabetes now in a Phase 1 trial (POLARIS). GentiBio has raised roughly $177M and signed a partnership with Bristol Myers Squibb worth up to $1.9B in potential milestones.

- **Founded:** 2020
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Adel Nada (Co-Founder, President & CEO), David Rawlings (Scientific Co-Founder (Seattle Children's Research Institute)), Jane Buckner (Scientific Co-Founder (Benaroya Research Institute)), Gideon (Gidi) Gross (Scientific Co-Founder (MIGAL Galilee Research Institute))
- **Team size:** ~45 employees
- **Products:** EngTreg platform, GNTI-122, GNTI-932, Additional pipeline (GNTI-148, GNTI-350, GNTI-823)
- **Notable:** Raised what the company described as the largest Series A in the Treg therapeutic space to date ($157M, 2021)., Signed a Bristol Myers Squibb collaboration worth up to $1.9B in potential milestones for IBD., Translated 2020 Science Translational Medicine FOXP3 gene-editing research into a clinical pipeline.

## Products & services

- **EngTreg platform** — A modular platform that engineers regulatory T cells from abundant autologous and allogeneic cell sources, using gene editing (including FOXP3) to produce stable, disease-specific, and tunable Tregs at scale - solving the rarity and phenotypic inconsistency of naturally isolated Tregs.
- **GNTI-122** — Lead program: a single-dose autologous antigen-specific engineered Treg therapy for recently diagnosed type 1 diabetes, designed to migrate to the pancreas and persist to preserve insulin production. In the POLARIS Phase 1 trial; received FDA IND clearance and Fast Track Designation.
- **GNTI-932** — Engineered Treg program targeting inflammatory bowel disease (IBD), the focus of the Bristol Myers Squibb collaboration.
- **Additional pipeline (GNTI-148, GNTI-350, GNTI-823)** — Earlier-stage engineered Treg programs spanning type 1 diabetes, B/T cell-driven autoimmune disease, and acute inflammatory conditions.

## Achievements

- Raised what the company described as the largest Series A in the Treg therapeutic space to date ($157M, 2021).
- Signed a Bristol Myers Squibb collaboration worth up to $1.9B in potential milestones for IBD.
- Translated 2020 Science Translational Medicine FOXP3 gene-editing research into a clinical pipeline.
- FDA acceptance of the IND for GNTI-122 (2025).
- FDA Fast Track Designation for GNTI-122 in recently diagnosed type 1 diabetes (2025).
- Dosed the first participant in the POLARIS Phase 1 trial of GNTI-122 (2026).

## Latest updates

- **2026-03** — First participant dosed in the POLARIS Phase 1 clinical trial of GNTI-122 for recently diagnosed type 1 diabetes.
- **2025-08** — FDA granted Fast Track Designation to GNTI-122 for recently diagnosed type 1 diabetes.
- **2025-07** — FDA accepted/cleared the IND application for GNTI-122.
- **2023** — Company conducted relatively small layoffs, citing a challenging biotech macro environment.
- **2022-08** — Announced collaboration with Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel disease (up to $1.9B in milestones).

## Links

- Website: https://gentibio.com
- LinkedIn: https://www.linkedin.com/company/gentibio
- Twitter/X: https://twitter.com/GentiBio

---

Profile page: https://yespress.io/gentibio
Published by YesPress — https://yespress.io
Last updated: 2026-06-15